Evidence map›Paper›PMID 40296903›Full record

ArticleOncology research2025

OTUB2 promotes proliferation and metastasis of triple-negative breast cancer by deubiquitinating TRAF6.

Y U Qiu, Ruihan Liu, Shanshan Huang, Qiaoting Cai, Y I Xie, Zhiting He, Weige Tan, Xinhua Xie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Research progress of DUB enzyme in breast cancer.Clinical and experimental medicine · 2025
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Y U QiuState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510030, China.
Ruihan LiuDepartment of Breast Surgery, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510030, China.
Shanshan HuangState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510030, China.
Qiaoting CaiState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510030, China.
Y I XieState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510030, China.
Zhiting HeState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510030, China.
Weige TanDepartment of Breast Surgery, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510030, China.
Xinhua XieState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510030, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Deubiquitinase OTUB2 plays a critical role in the progression of various tumors. However, its specific role in triple-negative breast cancer (TNBC) remains unclear. This study aims to elucidate the biological function of OTUB2 in TNBC and uncover the underlying mechanisms. Methods: First, we found that the expression of Results: Our results demonstrated that OTUB2 expression was elevated in TNBC and associated with poor prognosis. Overexpression of OTUB2 enhanced the proliferation and migration of TNBC cells, while its knockdown inhibited these processes. Moreover, OTUB2 stabilized tumor necrosis factor receptor-associated factor 6 (TRAF6) by deubiquitinating it, leading to activation of the protein kinase B (AKT) pathway. Conclusions: OTUB2 exerts its promoting effects on the progression of TNBC by activating the TRAF6/AKT pathway.

Indexed as

Deubiquitinating EnzymesTNF Receptor-Associated Factor 6Triple Negative Breast NeoplasmsCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsNeoplasm MetastasisPrognosisUbiquitinationDeubiquitinating EnzymesIntracellular Signaling Peptides and ProteinsTifab protein, humanTNF Receptor-Associated Factor 6DeubiquitinationOTUB2Triple-Negative Breast Cancer (TNBC)Tumor necrosis factor receptor-associated factor 6 (TRAF6)

Identifiers

PMID40296903
PMCPMC12034018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.